1.76
1.73%
0.03
시간 외 거래:
1.79
0.03
+1.70%
Zura Bio Ltd 주식(ZURA)의 최신 뉴스
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) - MSN
Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings - MarketBeat
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth - Yahoo Finance
Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA stock touches 52-week low at $1.97 amid market shifts - Investing.com Canada
Corporate Overview January 2025 Advancing Dual Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases - Marketscreener.com
Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase - Simply Wall St
Zura Bio’s (ZURA) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Zura Bio shares outlook positive as Phase 2 TibuSURE study evaluates key SSc complications - Investing.com India
Zura Bio begins Phase 2 study for systemic sclerosis treatment By Investing.com - Investing.com South Africa
Zura Bio initiates Phase II systemic sclerosis treatment trial - Yahoo Finance
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Quantisnow
17,442 Shares in Zura Bio Limited (NASDAQ:ZURA) Acquired by The Manufacturers Life Insurance Company - Defense World
Zura Bio FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
Zura Bio FY2025 EPS Forecast Boosted by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Zura Bio (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average PT from Analysts - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average Target Price from Analysts - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Update - Defense World
Zura Bio : to Present at the Piper Sandler 36th Annual Healthcare Conference Form 8 K - Marketscreener.com
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Zura Bio to Present at Piper Sandler Healthcare Conference, Showcasing Immunology Pipeline - StockTitan
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - Simply Wall St
HC Wainwright Reaffirms “Neutral” Rating for Zura Bio (NASDAQ:ZURA) - Defense World
HC Wainwright Reaffirms "Neutral" Rating for Zura Bio (NASDAQ:ZURA) - MarketBeat
GREAT POINT PARTNERS LLC Reduces Stake in Zura Bio Ltd - GuruFocus.com
ADAR1 Capital Management, LLC Acquires New Stake in Zura Bio Ltd - GuruFocus.com
Zura Bio advances Phase 2 study for systemic sclerosis treatment - Investing.com
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis - Yahoo Finance
HC Wainwright Has Positive Outlook for Zura Bio Q3 Earnings - MarketBeat
Guggenheim maintains Buy on Zura Bio, target steady at $15 - Investing.com India
Guggenheim maintains Buy on Zura Bio, target steady at $15 By Investing.com - Investing.com UK
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - BioSpace
Q3 Earnings Forecast for Zura Bio Issued By Leerink Partnrs - MarketBeat
Zura Bio (NASDAQ:ZURA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Piper Sandler sets price target on Zura Bio shares, cites positive trial data - Investing.com
Leerink Partners initiates Zura Bio stock with Outperform rating, $15 target - Investing.com
Zura Bio Ltd re-elects board, ratifies auditor at AGM By Investing.com - Investing.com Australia
Zura Bio to Participate in Two Upcoming Investor Conferences in November - Yahoo Finance
Zura Bio Ltd re-elects board, ratifies auditor at AGM - Investing.com India
Zura Bio announces departure of Chief Scientific Officer By Investing.com - Investing.com Australia
Zura Bio announces departure of Chief Scientific Officer - Investing.com India
자본화:
|
볼륨(24시간):